Compare Atmos Energy Corporation (ATO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Crispr Therapeutics AG — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.59B), while Crispr Therapeutics AG trades at $54.31 (market cap $5.23B). The key difference: Atmos Energy Corporation is far larger — about 5.5× Crispr Therapeutics AG's market cap, and Atmos Energy Corporation pays a 2.36% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ATO | CRSP | |
|---|---|---|
Market Cap | $28.59B | $5.23B |
Sector | Utilities | Health |
52-Week High | $192.25 | $76.78 |
52-Week Low | $162.44 | $44.34 |
Enterprise Value | $38.40B | $3.65B |
Dividend Yield | 2.36% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
